Platform Technology

Sagitta^©

Developing Therapies With no Compromise

Sagitta^© biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.

Sagitta^©

Developing Therapies With no Compromise

Sagitta^© biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.

Sagitta^© Bir
The lead candidate: RS-0139

Sagitta^© Dui
The lead candidate: RS-0337

Sagitta^© Radix

Sagitta^© Bir
The lead candidate: RS-0139

Sagitta^© Dui
The lead candidate: RS-0337

Sagitta^© Radix

HIGHER

THERAPEUTIC INDEX

The dual drug loading capacity of Sagitta^© yields to a synergistic therapeutic effect. Sagitta^© platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.

IMPROVED

PHARMACOKINETICS

Sagitta^© platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.

STRAIGHT-FORWARD

MANUFACTURING

We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs.

Efficacy & Specificity

· Versatile structure ·
· Synergistic therapeutic effect ·
· Higher accumulation ·

Translatability

· Pharmacokinetic parameters ·
· Predictable translation to human ·

Tolerability

· Reduced side effect profile ·
· Enhanced Permeability & Retention effect ·
· Selective release ·
· Biologic stimuli driven release ·

Manufacturability

· Proven GMP production record ·
· High purity ·
· Scalable for clinical GMP batches ·